Small Molecule Therapeutics for Schizophrenia (2015)
2. GlyT-1 Inhibitors: From Hits to Clinical Candidates
Roderick A. Porter and Lee A. Dawson
Roderick A. Porter and Lee A. Dawson
3. Metabotropic Glutamate Receptor 2 Activators
Jose´ M. Cid, Andre´s A. Trabanco, and Hilde Lavreysen
Jose´ M. Cid, Andre´s A. Trabanco, and Hilde Lavreysen
4. Activation of the mGlu5 Receptor for the Treatment of Schizophrenia and Cognitive-Deficit-Associated Disorders
Theresa Williams, Marlene A. Jacobson, Mikhail Kalinichev, and Jean-Philippe Rocher
Theresa Williams, Marlene A. Jacobson, Mikhail Kalinichev, and Jean-Philippe Rocher
5. Muscarinic Acetylcholine Receptor Activators
Takaaki Sumiyoshi and Takeshi Enomoto
Takaaki Sumiyoshi and Takeshi Enomoto
6. Nicotinic Acetylcholine Receptor Modulators
Anatoly Mazurov and Daniel Yohannes
Anatoly Mazurov and Daniel Yohannes
7. The Use of PDE10A and PDE9 Inhibitors for Treating Schizophrenia
Jamison B. Tuttle and Bethany L. Kormos
Jamison B. Tuttle and Bethany L. Kormos
Index